Drugs / AVOTACICLIB
AVOTACICLIB
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05769660 | Nov 2022 → Nov 2026 expected | glioblastoma | BeyondBio Inc. | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05093907 | Aug 2021 → Nov 2026 expected | colorectal cancer | BeyondBio Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03579836 | May 2018 → Nov 2026 expected | — | BeyondBio Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVOTACICLIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650328 ↗ |
| Known as | BEY1107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05093907 ↗ |
| Known as | Cdk1 inhibitor bey1107 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650328 ↗ |
| Modality | Small molecule | — CHEMBL4650328 ↗ |
| Route | Oral | “Take orally with water once a day” NCT03579836 ↗ |